Two ASX Healthcare Performers with Long Term Growth Potential

Mesoblast Limited (ASX: MSB)

Mesoblast Limited (ASX: MSB) has achieved a significant milestone with the FDA approval of Ryoncil® (remestemcel-L), marking the first mesenchymal stromal cell (MSC) therapy to gain approval in the U.S. This is a pivotal development for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients, addressing a condition with high unmet medical need and poor prognosis. Ryoncil® has demonstrated robust clinical efficacy, with a 70% overall response rate at Day 28 in a pivotal Phase 3 trial involving high-severity cases. The treatment's ability to deliver consistent and uninterrupted therapeutic benefits underscores its strong safety and efficacy profile. The approval of Ryoncil represents a landmark in regenerative medicine, positioning Mesoblast as a leader in the MSC space. With approximately 1,500 children undergoing bone marrow transplants annually in the U.S., and nearly half developing steroid-refractory aGvHD, Ryoncil is set to address a critical gap in the market.

Beyond Ryoncil, Mesoblast is advancing its pipeline, which includes Revascor® (rexlemestrocel-L) for end-stage heart failure and inflammatory pain, supported by the FDA's RMAT designation. These developments highlight the company's capacity to address both acute and chronic conditions with transformative cellular therapies. The company has also initiated a pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain, which could unlock a significant commercial opportunity. Financially, Mesoblast is positioned for growth, having secured $50 million to support the commercial launch of Ryoncil while implementing cost-saving measures to extend its financial runway. Leadership transitions have been smooth, with CEO Dr. Silviu Itescu driving regulatory engagement, clinical advancements, and commercial preparedness.

Looking ahead, Mesoblast's robust pipeline, combined with the validation of its platform through FDA approvals, suggests a strong growth trajectory. Investors can anticipate potential catalysts from pipeline progress, commercial launches, and strategic regulatory milestones. Mesoblast's innovative approach and disciplined execution position it to deliver substantial value for both patients and shareholders.

Orthocell Limited (ASX: OCC)

Orthocell Limited (ASX: OCC) is advancing its global commercialization strategy for Remplir™, its biological medical device designed for peripheral nerve repair. The company has successfully completed a pivotal U.S. FDA 510(k) regulatory study, meeting all critical endpoints. This study provided key data demonstrating Remplir’s safety and efficacy, including results showing that 85% of nerve reconstructions using Remplir resulted in functional muscle recovery. Based on this, Orthocell has submitted its FDA 510(k) application, with clearance anticipated in late March or early April 2025. The U.S. market for nerve repair is valued at over $1.6 billion, presenting a significant growth opportunity for the company.

Orthocell’s commercialization efforts are gaining traction across multiple markets. In Singapore, the company has achieved its first sales of Remplir ahead of the planned Q1 2025 launch, signaling strong demand. The device is also approved and selling in Australia and New Zealand, with growing sales and increasing adoption by surgeons. The company’s distribution partner, Device Technologies Asia, is driving the Singapore rollout, which serves as both a key market and a gateway to other ASEAN regions. These achievements reflect Orthocell’s commitment to global expansion and its strong distribution partnerships, which are central to the commercial success of Remplir.

The company’s financial position is strong, with approximately $33 million in cash and no debt, positioning Orthocell well for the U.S. market launch and further regulatory approvals. The U.S. launch is already in preparation, with new U.S. sales and medical affairs executives on board to lead the effort. Orthocell is also progressing with regulatory submissions in other key markets, including Canada, the UK, and Europe. The strong clinical data, expanding market presence, and financial stability indicate a promising future for Orthocell and its Remplir product in the global nerve repair market

Source: Company’s Report